Recently published data reveals, that miR-190b inhibition suppressed lipid accumulation and improved insulin sensitivity by targeting IGF1 and ADAMTS9, suggesting that miR-190b inhibition may be a therapeutic strategy against NAFLD [113]. The gene discussed is IGF1; the disease is metabolic dysfunction-associated steatotic liver disease.